Head-To-Head Analysis: Regenicin (OTCMKTS:RGIN) & Apyx Medical (NASDAQ:APYX)

Regenicin (OTCMKTS:RGIN) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Regenicin and Apyx Medical’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Apyx Medical	$52.35 million	0.90	-$18.71 million	($0.54)	-2.52

Regenicin has higher earnings, but lower revenue than Apyx Medical.

Institutional and Insider Ownership

0.0% of Regenicin shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 13.1% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Regenicin and Apyx Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Apyx Medical	-35.75%	-54.90%	-28.41%

Analyst Ratings

This is a summary of recent ratings and target prices for Regenicin and Apyx Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	N/A
Apyx Medical	0	0	2	0	3.00

Apyx Medical has a consensus price target of $6.17, indicating a potential upside of 353.43%.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.